Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As described below under Item 5.07 of this Current Report on Form 8-K, on June 7, 2022, Dynamics Special Purpose Corp. (“DYNS” or the “Company”) convened a Special Meeting of Stockholders (the “Special Meeting”) to approve, among other things, the previously announced business combination of the Company and Senti Biosciences, Inc. (the “Business Combination” and DYNS following the Business Combination, “New Senti”).
At the Special Meeting, the Company’s stockholders approved, among other items, the New Senti 2022 Equity Incentive Plan (the “Incentive Plan”) and the New Senti 2022 Employee Stock Purchase Plan (the “ESPP”). A description of the material terms of each of the Incentive Plan and ESPP is included in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 13, 2022 and first mailed to DYNS’ stockholders on or about May 13, 2022 (the “Proxy Statement”), which descriptions are incorporated herein by reference. Such descriptions do not purport to be complete and are qualified in their entirety by reference to the full text of the Incentive Plan and ESPP, which are attached as Annex C and Annex D, respectively, to the Proxy Statement and are also incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 7, 2022, DYNS convened the Special Meeting. At the Special Meeting, a total of 21,227,566 shares of Class A common stock and 5,750,000 shares of Class B common stock of DYNS, out of a total of 23,715,500 shares of Class A common stock and 5,750,000 shares of Class B common stock issued and outstanding and entitled to vote as of the close of business on May 3, 2022 (the record date for the Special Meeting), were present or represented by proxy at the Special Meeting. A summary of the voting results for the following proposals, each of which is described in detail in the Proxy Statement, is set forth below. The adjournment proposal described in the Proxy Statement was not presented at the Special Meeting because there were enough votes to approve the other proposals presented at the Special Meeting.
Proposal 1: Adoption of the Business Combination Proposal
DYNS’ stockholders, by ordinary resolution, (i) adopted and approved the Business Combination Agreement, dated as of December 19, 2021 (as amended or modified from time to time, the “Business Combination Agreement”), by and among DYNS, Explore Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of DYNS (“Merger Sub”), and Senti Biosciences, Inc., a Delaware corporation (“Senti”), pursuant to which Merger Sub will merge with and into Senti, with Senti surviving the merger as a wholly-owned subsidiary of DYNS, on the terms and subject to the conditions set forth therein; (ii) approved such merger and the other transactions contemplated by the Business Combination Agreement; and (iii) adopted and approved each document ancillary to the Business Combination Agreement to which DYNS is a party and all transactions contemplated therein. The following were the tabulated votes “For” and “Against” this proposal as well as the number of “Abstentions” and “Broker Non-Votes”:
| | | | | | |
FOR | | AGAINST | | ABSTAIN | | BROKER NON-VOTE |
23,617,750 | | 3,359,816 | | 0 | | 0 |